When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.83% and ...

Discover the first FDA-approved weight loss medication for obstructive sleep apnea, Zepbound by Eli Lilly. Learn how it can reduce apnea events and CPAP market.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...

Asian and European stock markets were largely getting off to a good start to a holiday-shortened Christmas week. Bargain hunting was in evidence as Novo Nordisk rose following a sharp drop for the ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

The statistics continue to be alarming, with no indication that the global rise in obesity is slowing. The real question ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...